Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp

Cancer Research

Volumn 65, Issue 16, 2005, Pages 7276-7282

  Nagai, Yoshiaki ^a   Miyazawa, Hitoshi ^a   Huqun, ^a   Tanaka, Tomoaki ^a   Udagawa, Kiyoshi ^a   Kato, Motoyasu ^a   Fukuyama, Shunichiro ^a   Yokote, Akemi ^a   Kobayashi, Kunihiko ^a   Kanazawa, Minoru ^a   Hagiwara, Koichi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ARTICLE; CANCER CELL CULTURE; CANCER MORTALITY; CAUSE OF DEATH; CONTROLLED STUDY; DRUG RESPONSE; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; PEPTIDE NUCLEIC ACID LOCKED NUCLEIC ACID POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; WILD TYPE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; GENE AMPLIFICATION; GENES, ERBB-1; GENETIC HETEROGENEITY; HUMANS; LUNG NEOPLASMS; MUTATION; PEPTIDE NUCLEIC ACIDS; POLYMERASE CHAIN REACTION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 23844465454     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0331     Document Type: Article

References (26)

1. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2002;2:37.
2. Pfister DG, Johnson DH, Azzoli CG. et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-53.
3. Ramalingam S, Belani CP. State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin Oncol 2004;31:68-74.
4. Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA Jr. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 2002;29:37-46.
5. Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa,' ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003;14:922-30.
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
7. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
8. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
9. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23.
10. Sarkar G, Sommer SS. The "megaprimer" method of site-directed mutagenesis. Biotechniques 1990;8:404-7.
11. Ugozzoli LA, Latorra D, Pucket R, Arar K, Hamby K. Real-time genotyping with oligonucleotide probes containing locked nucleic acids. Anal Biochem 2004;324: 143-52.
12. Wittung P, Nielsen PE, Buchardt O, Egholm M, Norden B. DNA-like double helix formed by peptide nucleic acid. Nature 1994;368:561-3.
13. Aebersold DM, Landt O, Berthou S, et al. Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx. Oncogene 2003;22:8519-23.
14. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996;6: 995-1001.
15. Hill C, Hunter SB, Brat DJ. Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Adv Anat Pathol 2003;10: 212-7.
16. Nielsen PE, editor. Peptide nucleic acids: protocols and applications. 2nd ed. Norwich (U.K.): Horizon Bioscience; 2004.
17. McTigue PM, Peterson RJ, Kahn JD. Sequence-dependent thermodynamic parameters for locked nucleic acid (LNA)-DNA duplex formation. Biochemistry 2004;43:5388-405.
18. Le Rhun Y, Duthu A, Ehrhart JC, Michiels F, May E, May P. Directional selection associated with clonal expansion of p53 mutant cells during neoplastic development of carcinogen-treated rat embryo lung epithelial cells. Oncogene 1994;9:263-71.
19. Chow M, Rubin H. Clonal selection versus genetic instability as the driving force in neoplastic transformation. Cancer Res 2000;60:6510-8.
20. Chu YW, Yang PC, Yang SC, et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 1997;17:353-60.
21. Mueller MM, Peter W, Mappes M, et al. Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Am J Pathol 2001;159:1567-79.
22. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53.
23. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-7.
24. Engelman JA, Janne PA, Mermel C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 2005;102:3788-93.
25. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004;10:8195-203.
26. Merlino G, Xu Y, Ishii S, et al. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science 1984;224:417-9.